Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site

References

• Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature 1985; 314:628 - 31; http://dx.doi.org/10.1038/314628a0; PMID: 2859527
   PubMed Web of Science ®Google Scholar
• Perez P, Hoffman RW, Shaw S, Bluestone JA, Segal DM. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 1985; 316:354 - 6; http://dx.doi.org/10.1038/316354a0; PMID: 3160953
   PubMed Web of Science ®Google Scholar
• Stamova S, Feldmann A, Cartellieri M, Arndt C, Koristka S, Apel F, et al. Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses. Anal Biochem 2012; 423:261 - 8; http://dx.doi.org/10.1016/j.ab.2011.12.042; PMID: 22274538
   PubMed Web of Science ®Google Scholar
• Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 2006; 43:763 - 71; http://dx.doi.org/10.1016/j.molimm.2005.03.007; PMID: 16360021
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 2005; 115:98 - 104; http://dx.doi.org/10.1002/ijc.20908; PMID: 15688411
   PubMed Web of Science ®Google Scholar
• Schlereth B, Fichtner I, Lorenczewski G, Kleindienst P, Brischwein K, da Silva A, et al. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res 2005; 65:2882 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-04-2637; PMID: 15805290
   PubMed Web of Science ®Google Scholar
• Weiner GJ, Hillstrom JR. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma. J Immunol 1991; 147:4035 - 44; PMID: 1834746
   PubMed Web of Science ®Google Scholar
• Demanet C, Brissinck J, Van Mechelen M, Leo O, Thielemans K. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3). J Immunol 1991; 147:1091 - 7; PMID: 1830596
   PubMed Web of Science ®Google Scholar
• Demanet C, Brissinck J, Leo O, Moser M, Thielemans K. Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma. Cancer Res 1994; 54:2973 - 8; PMID: 8187084
   PubMed Web of Science ®Google Scholar
• Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321:974 - 7; http://dx.doi.org/10.1126/science.1158545; PMID: 18703743
   PubMed Web of Science ®Google Scholar
• Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29:2493 - 8; http://dx.doi.org/10.1200/JCO.2010.32.7270; PMID: 21576633
   PubMed Web of Science ®Google Scholar
• Milstein C, Cuello AC. Hybrid hybridomas and their use in immunohistochemistry. Nature 1983; 305:537 - 40; http://dx.doi.org/10.1038/305537a0; PMID: 6137772
   PubMed Web of Science ®Google Scholar
• Holliger P, Prospero T, Winter G. “Diabodies”: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993; 90:6444 - 8; http://dx.doi.org/10.1073/pnas.90.14.6444; PMID: 8341653
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Bispecific Antibodies. Springer Berlin, 2011.
   Google Scholar
• Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002; 102:75 - 85; http://dx.doi.org/10.1002/ijc.10662; PMID: 12353237
   PubMed Web of Science ®Google Scholar
• Viti F, Tarli L, Giovannoni L, Zardi L, Neri D. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res 1999; 59:347 - 52; PMID: 9927045
   PubMed Web of Science ®Google Scholar
• Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, Von der Lieth CW, Matys ER, et al. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol 1999; 293:41 - 56; http://dx.doi.org/10.1006/jmbi.1999.3156; PMID: 10512714
   PubMed Web of Science ®Google Scholar
• Kipriyanov SM. Generation of bispecific and tandem diabodies. Methods Mol Biol 2009; 562:177 - 93; http://dx.doi.org/10.1007/978-1-60327-302-2_14; PMID: 19554296
   PubMedGoogle Scholar
• Seimetz D, Lindhofer H, Bokemeyer C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 2010; 36:458 - 67; http://dx.doi.org/10.1016/j.ctrv.2010.03.001; PMID: 20347527
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Kufer P, Zugmaier G, Baeuerle P. Dosage regimen for administering a CD19xCD3 bispecific antibody (Patent Nr.WO2011051307A1). In: WIPO/OMPI, ed., 2011.
   Google Scholar
• Cochlovius B, Kipriyanov SM, Stassar MJ, Schuhmacher J, Benner A, Moldenhauer G, et al. Cure of Burkitt’s lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation. Cancer Res 2000; 60:4336 - 41; PMID: 10969772
   PubMed Web of Science ®Google Scholar
• Shinkai Y, Koyasu S, Nakayama K, Murphy KM, Loh DY, Reinherz EL, et al. Restoration of T cell development in RAG-2-deficient mice by functional TCR transgenes. Science 1993; 259:822 - 5; http://dx.doi.org/10.1126/science.8430336; PMID: 8430336
   PubMed Web of Science ®Google Scholar
• Stork R, Campigna E, Robert B, Müller D, Kontermann RE. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J Biol Chem 2009; 284:25612 - 9; http://dx.doi.org/10.1074/jbc.M109.027078; PMID: 19628871
   PubMed Web of Science ®Google Scholar
• Castellani P, Viale G, Dorcaratto A, Nicolo G, Kaczmarek J, Querze G, et al. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 1994; 59:612 - 8; http://dx.doi.org/10.1002/ijc.2910590507; PMID: 7525495
   PubMed Web of Science ®Google Scholar
• Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P, et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 1998; 273:21769 - 76; http://dx.doi.org/10.1074/jbc.273.34.21769; PMID: 9705314
   PubMed Web of Science ®Google Scholar
• Zardi L, Carnemolla B, Siri A, Petersen TE, Paolella G, Sebastio G, et al. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J 1987; 6:2337 - 42; PMID: 2822387
   PubMed Web of Science ®Google Scholar
• Fattorusso R, Pellecchia M, Viti F, Neri P, Neri D, Wüthrich K. NMR structure of the human oncofoetal fibronectin ED-B domain, a specific marker for angiogenesis. Structure 1999; 7:381 - 90; http://dx.doi.org/10.1016/S0969-2126(99)80051-3; PMID: 10196121
   PubMed Web of Science ®Google Scholar
• Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003; 9:571 - 9; PMID: 12576420
   PubMed Web of Science ®Google Scholar
• Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 2009; 113:2265 - 74; http://dx.doi.org/10.1182/blood-2008-06-160416; PMID: 19131554
   PubMed Web of Science ®Google Scholar
• Erba PA, Sollini M, Orciuolo E, Traino C, Petrini M, Paganelli G, et al. Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies. J Nucl Med 2012; 53:922 - 7; http://dx.doi.org/10.2967/jnumed.111.101006; PMID: 22577235
   PubMed Web of Science ®Google Scholar
• Pasche N, Neri D. Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today 2012; 17:583 - 90; http://dx.doi.org/10.1016/j.drudis.2012.01.007; PMID: 22289353
   PubMed Web of Science ®Google Scholar
• Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005; 5:436 - 46; http://dx.doi.org/10.1038/nrc1627; PMID: 15928674
   PubMed Web of Science ®Google Scholar
• Ebbinghaus C, Ronca R, Kaspar M, Grabulovski D, Berndt A, Kosmehl H, et al. Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int J Cancer 2005; 116:304 - 13; http://dx.doi.org/10.1002/ijc.20952; PMID: 15800913
   PubMed Web of Science ®Google Scholar
• Melkko S, Halin C, Borsi L, Zardi L, Neri D. An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance. Int J Radiat Oncol Biol Phys 2002; 54:1485 - 90; http://dx.doi.org/10.1016/S0360-3016(02)03927-5; PMID: 12459375
   PubMed Web of Science ®Google Scholar
• Niesner U, Halin C, Lozzi L, Günthert M, Neri P, Wunderli-Allenspach H, et al. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjug Chem 2002; 13:729 - 36; http://dx.doi.org/10.1021/bc025517+; PMID: 12121127
   PubMed Web of Science ®Google Scholar
• Halin C, Niesner U, Villani ME, Zardi L, Neri D. Tumor-targeting properties of antibody-vascular endothelial growth factor fusion proteins. Int J Cancer 2002; 102:109 - 16; http://dx.doi.org/10.1002/ijc.10674; PMID: 12385005
   PubMed Web of Science ®Google Scholar
• Halin C, Gafner V, Villani ME, Borsi L, Berndt A, Kosmehl H, et al. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res 2003; 63:3202 - 10; PMID: 12810649
   PubMed Web of Science ®Google Scholar
• Gafner V, Trachsel E, Neri D. An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties. Int J Cancer 2006; 119:2205 - 12; http://dx.doi.org/10.1002/ijc.22101; PMID: 16823838
   PubMed Web of Science ®Google Scholar
• Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci USA 1987; 84:1374 - 8; http://dx.doi.org/10.1073/pnas.84.5.1374; PMID: 2950524
   PubMed Web of Science ®Google Scholar
• Alegre ML, Tso JY, Sattar HA, Smith J, Desalle F, Cole M, et al. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J Immunol 1995; 155:1544 - 55; PMID: 7636216
   PubMed Web of Science ®Google Scholar
• Amann M, Brischwein K, Lutterbuese P, Parr L, Petersen L, Lorenczewski G, et al. Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3. Cancer Res 2008; 68:143 - 51; http://dx.doi.org/10.1158/0008-5472.CAN-07-2182; PMID: 18172306
   PubMed Web of Science ®Google Scholar
• Schlereth B, Kleindienst P, Fichtner I, Lorenczewski G, Brischwein K, Lippold S, et al. Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3. Cancer Immunol Immunother 2006; 55:785 - 96; http://dx.doi.org/10.1007/s00262-005-0082-x; PMID: 16187083
   PubMed Web of Science ®Google Scholar
• Fiechter M, Frey K, Fugmann T, Kaufmann PA, Neri D. Comparative in vivo analysis of the atherosclerotic plaque targeting properties of eight human monoclonal antibodies. Atherosclerosis 2011; 214:325 - 30; http://dx.doi.org/10.1016/j.atherosclerosis.2010.11.027; PMID: 21167484
   PubMed Web of Science ®Google Scholar
• Silacci M, Brack S, Schirru G, Mårlind J, Ettorre A, Merlo A, et al. Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics 2005; 5:2340 - 50; http://dx.doi.org/10.1002/pmic.200401273; PMID: 15880779
   PubMed Web of Science ®Google Scholar
• Kim KS, Sun ZY, Wagner G, Reinherz EL. Heterodimeric CD3epsilongamma extracellular domain fragments: production, purification and structural analysis. J Mol Biol 2000; 302:899 - 916; http://dx.doi.org/10.1006/jmbi.2000.4098; PMID: 10993731
   PubMed Web of Science ®Google Scholar
• Tarli L, Balza E, Viti F, Borsi L, Castellani P, Berndorff D, et al. A high-affinity human antibody that targets tumoral blood vessels. Blood 1999; 94:192 - 8; PMID: 10381513
   PubMed Web of Science ®Google Scholar
• Demartis S, Tarli L, Borsi L, Zardi L, Neri D. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur J Nucl Med 2001; 28:534 - 9; http://dx.doi.org/10.1007/s002590100480; PMID: 11357506
   PubMedGoogle Scholar
• Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A, et al. Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 2003; 102:4384 - 92; http://dx.doi.org/10.1182/blood-2003-04-1039; PMID: 12933583
   PubMed Web of Science ®Google Scholar
• Bortoletto N, Scotet E, Myamoto Y, D’Oro U, Lanzavecchia A. Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells. Eur J Immunol 2002; 32:3102 - 7; http://dx.doi.org/10.1002/1521-4141(200211)32:11<3102::AID-IMMU3102>3.0.CO;2-C; PMID: 12385030
   PubMed Web of Science ®Google Scholar